PERSPECTA

News from every angle

← Back to headlines

CRISPR Therapeutics Stock Seen as Undervalued with High Upside Potential

CRISPR Therapeutics stock is considered to be significantly undervalued, with analysts projecting a substantial upside potential of 437%.

3 Jun, 16:50 — 3 Jun, 16:50
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual79d ago

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

Read full article →

Related Stories

China Recalls 4.3 Million Vehicles, Including Teslas, Over Safety Risks

20m ago

TikTok Settles US Child Privacy Case for $400 Million

34m ago

Moderna's Cancer Vaccine Breakthrough Boosts Biotech Hopes

1h ago

Iran Threatens Military Action Against US Sanctions

1h ago